Johnson & Johnson Stock Dips Following Mixed Q1 Results and Revised 2024 Outlook
• 1 min read
Healthcare giant Johnson & Johnson experienced a 2% stock decline after reporting mixed Q1 2024 results, with revenue beating expectations but earnings falling short. The company narrowed its full-year guidance amid market uncertainties while maintaining its status as a dividend aristocrat.